Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS

Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08. The non-GAAP range is the figure traders compare against consensus, and it depends on the newer launches offsetting the decline in Prolia and XGEVA.

• Total revenues guidance $38.2 billion to $39.4 billion
• Non-GAAP diluted EPS guidance $22.30 to $23.50
• GAAP diluted EPS guidance $15.80 to $17.08